XE9 Stock Chart & Stats
€16.90
€0.10(0.59%)
At close: 4:00 PM EDT
€16.90
€0.10(0.59%)
Day’s Range― - ―
52-Week Range€5.60 - €18.50
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€1.30B
Enterprise Value€637.69
Total Cash (Recent Filing)€456.45M
Total Debt (Recent Filing)€65.21M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 09, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding74,141,594
10 Day Avg. Volume22
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.04Price Target Upside42.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.32
Revenue Forecast (FY)€66.40M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA conservative capital structure with moderate-to-low leverage and a sizable equity cushion gives Xencor durable financial flexibility to fund R&D and absorb program setbacks. This reduces immediate refinancing risk and supports multi-year clinical development spending without forcing near-term distress financing.
Settlement Restores Near-term RunwayConverting disputed U.S. royalties into a $105M upfront settlement materially improves short-to-medium term funding visibility and reduces reliance on immediate capital markets. This creates a multi-year buffer to advance clinical programs and hit milestones without immediate dilution or emergency financing.
Technology Platform And Pipeline BreadthXencor's engineered antibody platform and diversified pipeline (multiple bispecifics and candidates across indications) provide structural competitive advantages: platform reusability, partner interest for licensing, and multiple independent clinical catalysts that increase long-term probability of at least one commercial success.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicate the company is not self-funding R&D and relies on external capital or milestone payments. Over time this elevates financing risk, potential dilution, and constrains the ability to scale programs if milestone timings slip or partner payments delay.
Volatile Revenue And Ongoing LossesRevenue volatility and entrenched operating losses signal weak earnings power from current operations. Inconsistent margins and swings in recognized collaboration revenue make forecasting cash runway and funding needs difficult, increasing the likelihood of future capital raises that can dilute shareholders.
Loss Of Recurring U.S. Royalty StreamWhile the settlement provides upfront cash, it removes a potential long-term recurring U.S. royalty revenue stream. That structural loss reduces ongoing revenue upside and recurring cash flow beyond the settlement period, making future revenue more dependent on new approvals, partners, or sporadic milestones.
Xencor News
XE9 FAQ
What was Xencor Inc’s price range in the past 12 months?
Xencor Inc lowest stock price was €5.60 and its highest was €18.50 in the past 12 months.
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is €1.30B.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is Nov 09, 2026 which is in 94 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on Aug 05, 2026. The company reported -€0.251 earnings per share for the quarter, beating the consensus estimate of -€0.693 by €0.442.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.27.
How many shares outstanding does Xencor Inc have?
Xencor Inc has 74,141,594 shares outstanding.
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -€0.251 in its last earnings report, beating expectations of -€0.693. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in DE:XE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.04 (42.22% Upside)
€24.04 (42.22% Upside)
Blogger Sentiment
Bullish
DE:XE9 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XE9 Stock 12 Month Forecast
Average Price Target
€24.04
▲(42.22% Upside)
Technical Analysis
CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―